This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

Advanced Search

Project: Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium difficile Infection [Entered Retrospectively]

Public Report Complete

Project Summary

Title and Description

Key Questions

Associated Studies (each link opens a new tab)

Title Author Year
Evaluation of diagnostic tests for Clostridium difficile infection. Swindells J., Brenwald N., Reading N., Oppenheim B. 2010
Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. Kvach EJ., Ferguson D., Riska PF., Landry ML. 2010
Comparison of ImmunoCard Toxins A&B and the new semiautomated Vidas Clostridium difficile Toxin A&B tests for diagnosis of C. difficile infection. Alcalá L., Marín M., Madrid M., Domínguez-García E., Catalán P., Peláez MT., Sánchez-Somolinos M., Bouza E. 2010
Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. Eastwood K., Else P., Charlett A., Wilcox M. 2009
Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. Novak-Weekley SM., Marlowe EM., Miller JM., Cumpio J., Nomura JH., Vance PH., Weissfeld A. 2010
Comparison of three commercial methods for rapid detection of Clostridium difficile toxins A and B from fecal specimens. Alcalá L., Sánchez-Cambronero L., Catalán MP., Sánchez-Somolinos M., Peláez MT., Marín M., Bouza E. 2008
Diagnostic value of five commercial tests for the rapid diagnosis of Clostridium difficile-associated disease. Miendje Deyi VY., Vandenberg O., Mascart G., Gning S., Retore P., Douat N., Dediste A. 2008
Evaluation of two rapid immunochromatography tests for the detection of Clostridium difficile toxins. Samra Z., Luzon A., Bishara J. 2008
Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. Sloan LM., Duresko BJ., Gustafson DR., Rosenblatt JE. 2008
Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. Musher DM., Manhas A., Jain P., Nuila F., Waqar A., Logan N., Marino B., Graviss EA. 2007
Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. van den Berg RJ., Vaessen N., Endtz HP., Schülin T., van der Vorm ER., Kuijper EJ. 2007
Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. Turgeon DK., Novicki TJ., Quick J., Carlson L., Miller P., Ulness B., Cent A., Ashley R., Larson A., Coyle M., Limaye AP., Cookson BT., Fritsche TR. 2003
Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea. O'Connor D., Hynes P., Cormican M., Collins E., Corbett-Feeney G., Cassidy M. 2001
Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Peled N., Pitlik S., Samra Z., Kazakov A., Bloch Y., Bishara J. 2007
Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure. Samore MH., Venkataraman L., DeGirolami PC., Merrigan MM., Johnson S., Gerding DN., Carmeli Y., Harbarth S. 2006
Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Yearsley KA., Gilby LJ., Ramadas AV., Kubiak EM., Fone DL., Allison MC. 2006
Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Vesta KS., Wells PG., Gentry CA., Stipek WJ. 2005
Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Kyne L., Sougioultzis S., McFarland LV., Kelly CP. 2002
Clostridium difficile-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. Mody LR., Smith SM., Dever LL. 2001
Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Schwaber MJ., Simhon A., Block C., Roval V., Ferderber N., Shapiro M. 2000
Predicting Clostridium difficile stool cytotoxin results in hospitalized patients with diarrhea. Katz DA., Bates DW., Rittenberg E., Onderdonk A., Sands K., Barefoot LA., Snydman D. 1997
Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. Fowler S., Webber A., Cooper BS., Phimister A., Price K., Carter Y., Kibbler CC., Simpson AJ., Stone SP. 2007
Interventions to improve antibiotic prescribing practices for hospital inpatients. Davey P., Brown E., Fenelon L., Finch R., Gould I., Hartman G., Holmes A., Ramsay C., Taylor E., Wilcox M., Wiffen P. 2005
Antibiotic prescribing policy and Clostridium difficile diarrhoea. O'Connor KA., Kingston M., O'Donovan M., Cryan B., Twomey C., O'Mahony D. 2004
Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. Wilcox MH., Freeman J., Fawley W., MacKinlay S., Brown A., Donaldson K., Corrado O. 2004
An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Ludlam H., Brown N., Sule O., Redpath C., Coni N., Owen G. 1999
Nosocomial Clostridium difficile colonisation and disease. Johnson S., Clabots CR., Linn FV., Olson MM., Peterson LR., Gerding DN. 1990
Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Brooks SE., Veal RO., Kramer M., Dore L., Schupf N., Adachi M. 1992
Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Brooks S., Khan A., Stoica D., Griffith J., Friedeman L., Mukherji R., Hameed R., Schupf N. 1998
A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Jernigan JA., Siegman-Igra Y., Guerrant RC., Farr BM. 1998
Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection. Kaier K., Hagist C., Frank U., Conrad A., Meyer E. 2009
Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. Vernaz N., Sax H., Pittet D., Bonnabry P., Schrenzel J., Harbarth S. 2008
Prospective, controlled, cross-over trial of alcohol-based hand gel in critical care units . Rupp ME., Fitzgerald T., Puumala S., Anderson JR., Craig R., Iwen PC., Jourdan D., Keuchel J., Marion N., Peterson D., Sholtz L., Smith V. 2008
Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Gordin FM., Schultz ME., Huber RA., Gill JA. 2005
Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Hacek DM., Ogle AM., Fisher A., Robicsek A., Peterson LR. 2010
Environmental control to reduce transmission of Clostridium difficile. Mayfield JL., Leet T., Miller J., Mundy LM. 2000
Acquisition of Clostridium difficile from the hospital environment. Kaatz GW., Gitlin SD., Schaberg DR., Wilson KH., Kauffman CA., Seo SM., Fekety R. 1988
Control of nosocomial transmission of Clostridium difficile based on sporadic case surveillance. Struelens MJ., Maas A., Nonhoff C., Deplano A., Rost F., Serruys E., Delmee M. 1991
Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated Clostridium difficile infection. Abbett SK., Yokoe DS., Lipsitz SR., Bader AM., Berry WR., Tamplin EM., Gawande AA. 2009
Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Boyce JM., Havill NL., Otter JA., McDonald LC., Adams NM., Cooper T., Thompson A., Wiggs L., Killgore G., Tauman A., Noble-Wang J. 2008
Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Drudy D., Harnedy N., Fanning S., Hannan M., Kyne L. 2007
Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Valiquette L., Cossette B., Garant MP., Diab H., Pépin J. 2007
Designing a protocol that eliminates Clostridium difficile: a collaborative venture. Whitaker J., Brown BS., Vidal S., Calcaterra M. 2007
Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Zafar AB., Gaydos LA., Furlong WB., Nguyen MH., Mennonna PA. 1998
Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. McNulty C., Logan M., Donald IP., Ennis D., Taylor D., Baldwin RN., Bannerjee M., Cartwright KA. 1997
Management and control of a large outbreak of diarrhoea due to Clostridium difficile. Cartmill TD., Panigrahi H., Worsley MA., McCann DC., Nice CN., Keith E. 1994
Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Pear SM., Williamson TH., Bettin KM., Gerding DN., Galgiani JN. 1994
Risk factors for Clostridium difficile toxin-associated diarrhea. Brown E., Talbot GH., Axelrod P., Provencher M., Hoegg C. 1990
Use of hypochlorite solution to decrease rates of Clostridium difficile-associated diarrhea. McMullen KM., Zack J., Coopersmith CM., Kollef M., Dubberke E., Warren DK. 2007
Risk factors for Clostridium difficile infection. Bignardi GE. 1998
Fidaxomicin versus vancomycin for Clostridium difficile infection. Louie TJ., Miller MA., Mullane KM., Weiss K., Lentnek A., Golan Y., Gorbach S., Sears P., Shue YK. 2011
Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Musher DM., Logan N., Bressler AM., Johnson DP., Rossignol JF. 2009
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Zar FA., Bakkanagari SR., Moorthi KM., Davis MB. 2007
Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Lagrotteria D., Holmes S., Smieja M., Smaill F., Lee C. 2006
Nitazoxanide for the treatment of Clostridium difficile colitis. Musher DM., Logan N., Hamill RJ., Dupont HL., Lentnek A., Gupta A., Rossignol JF. 2006
A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. Wullt M., Odenholt I. 2004
Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Norén T., Wullt M., Akerlund T., Bäck E., Odenholt I., Burman LG. 2006
Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Wenisch C., Parschalk B., Hasenhündl M., Hirschl AM., Graninger W. 1996
Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. de Lalla F., Nicolin R., Rinaldi E., Scarpellini P., Rigoli R., Manfrin V., Tramarin A. 1992
Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Fekety R., Silva J., Kauffman C., Buggy B., Deery HG. 1989
Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Dudley MN., McLaughlin JC., Carrington G., Frick J., Nightingale CH., Quintiliani R. 1986
Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Young GP., Ward PB., Bayley N., Gordon D., Higgins G., Trapani JA., McDonald MI., Labrooy J., Hecker R. 1985
Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Teasley DG., Gerding DN., Olson MM., Peterson LR., Gebhard RL., Schwartz MJ., Lee JT. 1983
Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Keighley MR., Burdon DW., Arabi Y., Williams JA., Thompson H., Youngs D., Johnson M., Bentley S., George RH., Mogg GA. 1978
A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Mattila E., Anttila VJ., Broas M., Marttila H., Poukka P., Kuusisto K., Pusa L., Sammalkorpi K., Dabek J., Koivurova OP., Vähätalo M., Moilanen V., Widenius T. 2008
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Surawicz CM., McFarland LV., Greenberg RN., Rubin M., Fekety R., Mulligan ME., Garcia RJ., Brandmarker S., Bowen K., Borjal D., Elmer GW. 2000
Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Wullt M., Hagslätt ML., Odenholt I. 2003
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. McFarland LV., Surawicz CM., Greenberg RN., Fekety R., Elmer GW., Moyer KA., Melcher SA., Bowen KE., Cox JL., Noorani Z. -- Not Found --
Randomized controlled trial of colestipol in antibiotic-associated colitis. Mogg GA., George RH., Youngs D., Johnson M., Thompson H., Burdon DW., Keighley MR. 1982
Systemic absorption of oral cholestyramine. McDonald GB., Vracko R. 1984
Recurrent Clostridium difficile-associated colitis responding to cholestyramine. Kunimoto D., Thomson AB. 1986
Effects of combination therapy with direct hemoperfusion using polymyxin B-immobilized fiber and oral vancomycin on fulminant pseudomembranous colitis with septic shock. Kimura Y., Sato K., Tokuda H., Nakamura N., Dohi Y., Orito E., Mizokami M. 2007
Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Tvede M., Rask-Madsen J. 1989
Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Persky SE., Brandt LJ. 2000
Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. MacConnachie AA., Fox R., Kennedy DR., Seaton RA. 2009
Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. Rohlke F., Surawicz CM., Stollman N. 2010
Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. Yoon SS., Brandt LJ. 2010
Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Silverman MS., Davis I., Pillai DR. 2010
Yoghurt biotherapy: contraindicated in immunosuppressed patients? MacGregor G., Smith AJ., Thakker B., Kinsella J. 2002
A case of recurrent Clostridium difficile diarrhea. Pakyz A. 2007
Saccharomyces cerevisiae fungemia: an emerging infectious disease. Muñoz P., Bouza E., Cuenca-Estrella M., Eiros JM., Pérez MJ., Sánchez-Somolinos M., Rincón C., Hortal J., Peláez T. 2005
Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Seal D., Borriello SP., Barclay F., Welch A., Piper M., Bonnycastle M. 1987
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Taylor CP., Tummala S., Molrine D., Davidson L., Farrell RJ., Lembo A., Hibberd PL., Lowy I., Kelly CP. 2008
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Herpers BL., Vlaminckx B., Burkhardt O., Blom H., Biemond-Moeniralam HS., Hornef M., Welte T., Kuijper EJ. 2009
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., Giannasca PJ., Lee CK., Warny M., Monath TP., Kelly CP. 2005
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Kotloff KL., Wasserman SS., Losonsky GA., Thomas W., Nichols R., Edelman R., Bridwell M., Monath TP. 2001
Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. McPherson S., Rees CJ., Ellis R., Soo S., Panter SJ. 2006
Intravenous immunoglobulin for resistant Clostridium difficile infection. Murphy C., Vernon M., Cullen M. 2006
Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Hassoun A., Ibrahim F. 2007
Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. Abougergi MS., Broor A., Cui W., Jaar BG. 2010
Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Surawicz CM., Elmer GW., Speelman P., McFarland LV., Chinn J., van Belle G. 1989
Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. McFarland LV., Surawicz CM., Greenberg RN., Elmer GW., Moyer KA., Melcher SA., Bowen KE., Cox JL. 1995
The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. Lewis SJ., Potts LF., Barry RE. 1998
Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Thomas MR., Litin SC., Osmon DR., Corr AP., Weaver AL., Lohse CM. 2001
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Plummer S., Weaver MA., Harris JC., Dee P., Hunter J. 2004
Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Lewis S., Burmeister S., Cohen S., Brazier J., Awasthi A. 2005
Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Can M., Beşirbellioglu BA., Avci IY., Beker CM., Pahsa A. 2006
Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Lewis S., Burmeister S., Brazier J. 2005
Treatment with monoclonal antibodies against Clostridium difficile toxins. Lowy I., Molrine DC., Leav BA., Blair BM., Baxter R., Gerding DN., Nichol G., Thomas WD., Leney M., Sloan S., Hay CA., Ambrosino DM. 2010
Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. Hickson M., D'Souza AL., Muthu N., Rogers TR., Want S., Rajkumar C., Bulpitt CJ. 2007
Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Planche T., Aghaizu A., Holliman R., Riley P., Poloniecki J., Breathnach A., Krishna S. 2008
Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. Garey KW., Sethi S., Yadav Y., DuPont HL. 2008
Systematic review of the risk of enteric infection in patients taking acid suppression. Leonard J., Marshall JK., Moayyedi P. 2007
How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. Kramer A., Schwebke I., Kampf G. 2006
Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Koo HL., Koo DC., Musher DM., DuPont HL. 2009
Probiotics for treatment of Clostridium difficile-associated colitis in adults. Pillai A., Nelson R. 2008
Are probiotic or synbiotic preparations effective for the management of clostridium difficile-associated or radiation-induced diarrhea? Eddins C., Gray M. -- Not Found --
Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Segarra-Newnham M. 2007
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. McFarland LV. 2006
Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. Dendukuri N., Costa V., McGregor M., Brophy JM. 2005
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Bricker E., Garg R., Nelson R., Loza A., Novak T., Hansen J. 2005
Review article: treatment of Clostridium difficile infection. Zimmerman MJ., Bak A., Sutherland LR. 1997

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: